Dexcom (NASDAQ: DXCM) EVP granted 43,897 RSUs vesting through 2029

Rhea-AI Filing Summary

Coleman Jon reported acquisition or exercise transactions in this Form 4 filing.

Dexcom EVP and Chief Commercial Officer Jon Coleman received a grant of 43,897 restricted stock units (RSUs) of Dexcom common stock. These RSUs vest in three equal annual installments from the March 8, 2026 grant date. After this award, Coleman holds 112,635 unvested RSUs in total, scheduled to vest through dates extending to 2029.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coleman Jon

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	43,897	$0.00	--

Holdings After Transaction: Common Stock — 112,635 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Included in this number are 112,635 unvested RSUs, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 68,738 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Jon

(Last) (First) (Middle)

6430 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		A		43,897(1)	A	$0	112,635(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Included in this number are 112,635 unvested RSUs, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 68,738 of which were granted on May 22, 2025 and shall vest through May 22, 2029.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Jon Coleman	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dexcom (DXCM) executive Jon Coleman report on this Form 4?

Jon Coleman reported receiving a grant of 43,897 restricted stock units. These RSUs are part of his equity compensation and provide a contingent right to receive Dexcom common shares, aligning his incentives with long-term company performance as they vest over time.

How many Dexcom (DXCM) RSUs does Jon Coleman hold after this grant?

After this grant, Jon Coleman holds 112,635 unvested restricted stock units. This total includes 43,897 RSUs granted on March 8, 2026 and 68,738 RSUs granted on May 22, 2025, all subject to multi-year vesting schedules that extend through 2029.

What are the vesting terms of Jon Coleman’s new Dexcom (DXCM) RSUs?

The 43,897 RSUs granted to Jon Coleman vest in three equal annual installments. Vesting begins one year from the March 8, 2026 grant date and continues annually, providing long-term retention incentives tied to his continued service and Dexcom’s ongoing performance.

Are Jon Coleman’s Dexcom (DXCM) RSUs immediately owned common shares?

No, the RSUs are a contingent right to receive Dexcom common stock. Coleman only receives actual shares as each portion of the RSUs vests over time, meaning his effective ownership increases gradually rather than all at once on the grant date.

Do these Dexcom (DXCM) RSU grants involve an open-market purchase or sale?

No, the Form 4 shows a grant or award acquisition of RSUs, not an open-market trade. Coleman did not buy or sell shares for cash; instead, he received equity-based compensation that converts into shares as vesting conditions are met over several years.